Lola Iskhakova
Internal Medicine · Ozone Park, NYNPI 1003157058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 33.7% of the total. 2025 is the largest year on record at $1,326, more than ten times the $38 reported in 2020.
Across 122 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Redhill Biopharma Inc.$583
- Novo Nordisk$435
- Axsome Therapeutics, Inc.$341
- Mannkind Corporation$153
- Lilly USA, LLC$137
- plus $454 from 9 others
What the payments were for
- Food & beverage$3,07097%
- Education$431%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $1,068 |
| Redhill Biopharma Inc. | 31 | $583 |
| Novo Nordisk | 6 | $435 |
| Axsome Therapeutics, Inc. | 10 | $341 |
| Mannkind Corporation | 4 | $153 |
| Lilly USA, LLC | 7 | $137 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $130 |
| Shield Therapeutics Inc | 6 | $105 |
| Dexcom, Inc. | 3 | $65 |
| Amgen(2 entities) | 3 | $46 |
| Phadia US Inc. | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Insulet Corporation | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Merz North America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,172 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $25,813 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $15,441 |
| Diclofenac Sodium | 28 | $11,861 |
| OzempicSemaglutide | 13 | $11,743 |
| Memantine Hcl ErMemantine Hcl | 38 | $2,582 |
| Omeprazole | 44 | $506 |
| Losartan Potassium | 63 | $468 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 22 | $416 |
| Gabapentin | 46 | $365 |
| Rosuvastatin Calcium | 50 | $342 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $341 |
| Memantine Hcl | 15 | $305 |
| Citalopram HbrCitalopram Hydrobromide | 17 | $302 |
| Atorvastatin Calcium | 56 | $248 |
| Simvastatin | 13 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $435 | $11,74313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Ozone Park
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.